Single dose is 200 mg (total dose) and 6 mg per kg.

Oocytes were perfused at room temperature (20—25°C), in a 300-mkl chamber with perfusion solution [115 mM NaC1, 1.8 mM CaC12, 2.5 mM KC1, 10 mM HEPES (pH 7.2), and 1.0 mkM atropine 1. Perfusion was at a continuous rate of ~20 ml/min. ACh was diluted in perfusion solution, and the oocytes were exposed to ACh for ~10 s, using a solenoid valve. DH/3E sensitivity was tested by measuring the reduction of ACh-induced current responses when Dihydro-β-erythroidine was coapplied with ACh. The ACh-induced response recorded during coapplication with Dihydro-β-erythroidine is reported as a percentage of the response to ACh alone. Current responses to agonist application were measured under two-electrode voltage-clamp using a Knight Industrial Technologies (Miami, FL, U.S.A.) unit. All experiments were conducted at a holding potential of —70 mV, except for someof the ACh dose—responseand Dihydro-β-erythroidine dose—inhibition experiments involving alpha4/beta2 and alpha2/beta4, which were done at —30 mY. We have found that pharmacological measurements are identical at both holding potentials. Micropipettes were filled with 3 M KC1 and had resistances of 0.5—3.0 M. Agonist-induced responses were captured, stored, and analyzed on a Macintosh IIci computer using a data acquisition program written with LabVIEW (National Instruments) and LIBI (University of Arizona) software